Oruka Therapeutics, Inc. (ORKA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 FY14: 0 FY15: 0 FY16: 0 FY17: 0 FY18: 0 FY19: 0 FY20: 0 FY21: 0 FY22: 0 FY23: 0 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY10: -9.2M FY11: -7.4M FY12: -4.3M FY13: -6.9M FY14: -9.7M FY15: -11.5M FY16: -16.6M FY17: -18.7M FY18: -8.1M FY19: -5.8M FY20: -9.8M FY21: -19.3M FY22: -10.6M FY23: -7.3M FY25: -122.1M FY10 FY12 FY14 FY16 FY18 FY20 FY22 FY25

Net Income Annual

-120M -80M -40M 0 40M 80M 120M FY04: -511K FY05: -1.5M FY06: -5.2M FY07: -14M FY08: -19.4M FY09: -9.1M FY10: -8.4M FY11: -5.4M FY12: -4.3M FY13: -6.9M FY14: -9.7M FY15: -11.4M FY16: -16.4M FY17: -18.5M FY18: -7.9M FY19: -5.5M FY20: -9.7M FY21: -19.3M FY22: -9.9M FY23: -5.3M FY24: -83.7M FY25: -105.4M FY05 FY07 FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M FY10: -8.3M FY11: -7M FY12: -4.1M FY13: -5.3M FY14: -9.4M FY15: -10.5M FY16: -15M FY17: -17.5M FY18: -8.2M FY19: -4.8M FY20: -7.7M FY21: -18.8M FY22: -10.9M FY23: -5M FY25: -88.2M FY10 FY12 FY14 FY16 FY18 FY20 FY22 FY25

Free Cash Flow Annual

-105M -70M -35M 0 35M 70M 105M FY10: -8.3M FY11: -7M FY13: -5.3M FY14: -9.4M FY15: -10.5M FY16: -15M FY17: -17.5M FY18: -8.2M FY19: -4.8M FY20: -7.7M FY21: -18.8M FY22: -10.9M FY23: -5M FY25: -88.4M FY11 FY14 FY16 FY18 FY20 FY22 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 7M 14M 21M FY11: 1.7M FY12: 2.2M FY13: 8.6M FY14: 20.5M FY21: 13.9M FY22: 14.4M FY23: 14.4M FY11 FY12 FY13 FY14 FY21 FY22 FY23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q4 '10: -0.99 Q1 '11: -0.93 Q2 '11: -0.64 Q3 '11: -0.57 Q4 '11: -3.22 Q1 '12: -3.66 Q2 '12: -3.78 Q3 '12: -4.02 Q4 '12: -1.48 Q1 '13: -1.14 Q2 '13: -1.70 Q3 '13: -1.45 Q4 '13: -1.24 Q1 '14: -1.02 Q2 '14: -0.48 Q3 '15: -2.78 Q4 '15: -2.19 Q1 '16: -1.68 Q2 '16: -1.42 Q3 '16: -1.62 Q4 '16: -1.80 Q1 '17: -1.88 Q2 '17: -2.04 Q3 '17: -1.92 Q4 '17: -1.80 Q1 '18: -4.93 Q2 '18: -7.08 Q3 '18: -8.75 Q4 '18: -10.33 Q1 '19: -8.58 Q2 '19: -6.98 Q3 '19: -5.68 Q4 '19: -4.45 Q1 '20: -3.42 Q2 '20: -3.01 Q3 '20: -2.58 Q4 '20: -2.50 Q1 '21: -2.00 Q2 '21: -1.61 Q3 '21: -1.61 Q4 '21: -1.40 Q1 '22: -1.30 Q2 '22: -1.18 Q3 '22: -1.01 Q4 '22: -0.69 Q1 '23: -0.55 Q2 '23: -0.43 Q3 '23: -0.37 Q4 '23: -0.37 Q1 '24: -0.42 Q2 '24: -7.28 Q3 '24: -8.64 Q4 '24: -6.35 Q1 '25: -6.61 Q2 '25: -0.11 Q1 '12 Q4 '13 Q3 '16 Q2 '18 Q1 '20 Q4 '21 Q3 '23 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.